Proton pump inhibitor concomitant use to prevent oxaliplatin‐induced peripheral neuropathy: Clinical retrospective cohort study

Figures

• 

  FIGURE 1. Classification of patients surveyed. The study included 1180 patients starting oxaliplatin‐related regimens. Of these, 165 were patients with diabetes and were excluded from subsequent analyses, leaving 1015 patients. Of the 1015 patients, 205 were in the proton pump inhibitor (PPI) group and 810 were in the no‐PPI group. Propensity score matching was performed, and 193 participants in the PPI group were matched with the corresponding 193 participants in the no‐PPI group.

• 

  FIGURE 2. Kaplan–Meier curves of cumulative incidence of oxaliplatin‐induced peripheral neuropathy (OIPN) (before propensity score matching). Kaplan–Meier curves were constructed with oxaliplatin discontinuation due to OIPN (A), incidence of OIPN (any grade) (B), ≥ Grade 2 (C), ≥ Grade 3 (D), and oxaliplatin dose reduction due to OIPN (E) on the y‐axis and the cumulative dose of oxaliplatin on the x‐axis. Differences in cumulative incidence between the proton pump inhibitor (PPI) and no‐PPI groups were analyzed using the log‐rank test.

• 

  FIGURE 3. Multivariate analysis of variables associated with oxaliplatin discontinuation due to oxaliplatin‐induced peripheral neuropathy (OIPN) (before propensity score matching). Cox proportional hazards analysis was then performed incorporating factors reported to influence OIPN (sex, regimen, age, use of proton pump inhibitors, use of opioids, use of adjuvant analgesics, and use of calcium channel blockers) as covariates.

• 

  FIGURE 4. Kaplan–Meier curves of cumulative incidence of oxaliplatin‐induced peripheral neuropathy (OIPN) (after propensity score matching). Kaplan–Meier curves were constructed with oxaliplatin discontinuation due to OIPN (A), incidence of OIPN (any grade) (B), ≥ Grade 2 (C), ≥ Grade 3 (D), and oxaliplatin dose reduction due to OIPN (E) on the y‐axis and the cumulative dose of oxaliplatin on the x‐axis. Differences in cumulative incidence between the proton pump inhibitor (PPI) and no‐PPI groups were analyzed using the log‐rank test.

• 

  FIGURE 5. Multivariate analysis of variables associated with oxaliplatin discontinuation due to oxaliplatin‐induced peripheral neuropathy (OIPN) (after propensity score matching). Cox proportional hazards analysis was then performed incorporating factors reported to influence OIPN (sex, regimen, age, use of proton pump inhibitors, use of opioids, use of adjuvant analgesics, and use of calcium channel blockers) as covariates.